CoMind has raised $102.5 million in a new funding round led by Plural, with participation from existing investors Angelini Ventures, LocalGlobe, Octopus Ventures, Crane, Backed VC, and Entrepreneurs First. The funding will support regulatory approval of CoMind’s first product, CoMind One, alongside further clinical trials, team expansion, and manufacturing partnerships. The company aims to transform the way critical brain data is captured and used in medical settings.
CoMind One is designed to provide continuous, bedside insights into cerebral blood flow, cerebral autoregulation, and intracranial pressure, helping doctors make precise, timely decisions in critical care settings. The technology addresses a long-standing challenge where medical professionals have had to choose between highly invasive monitoring methods or less reliable non-invasive options. The new funding marks a significant step toward making advanced brain monitoring safer, more accessible, and clinically effective.
